A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorDizal Pharmaceuticals
About this trial
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL.
This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
Eligibility criteria
Qualifiers
Male and female ≥ 18 years of age.
ECOG performance status 0-2, and life expectancy ≥ 6 months.
Confirmed newly diagnosis or treatment naïve CLL/SLL with indication for treatment.
Patients with SLL must have at least one measurable lesion.
Disqualifiers
Any of previous or current treatment prohibited by protocol.
Any unresolved > grade 1 drug-related adverse events.
Known or suspected Richter's transformation, or prolymphocytic leukemia.
CNS involvement.
Trial design
Treatments tested in this trial
- DZD8586
- Venetoclax
Treatment groups
66 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov